Antibody response to enterotoxigenic Bacteroides fragilis of Filipino colorectal cancer patients

IF 0.4 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Asian Biomedicine Pub Date : 2023-12-28 DOI:10.2478/abm-2023-0070

Ana Maria D. Cariño, Gregg Austine Balanag, Edrienne Myenna Magat, Allan Fellizar, Teresa Sy Ortin, Oliver Villaflores, Leonardo Guevarra, Pia Marie Albano

{"title":"Antibody response to enterotoxigenic Bacteroides fragilis of Filipino colorectal cancer patients","authors":"Ana Maria D. Cariño, Gregg Austine Balanag, Edrienne Myenna Magat, Allan Fellizar, Teresa Sy Ortin, Oliver Villaflores, Leonardo Guevarra, Pia Marie Albano","doi":"10.2478/abm-2023-0070","DOIUrl":null,"url":null,"abstract":"Background Several species of the gut microbiota have been implicated in colorectal cancer (CRC) development. The anaerobic bacterium enterotoxigenic Bacteroides fragilis (ETBF), has been identified to produce fragilysin, a toxin known to cleave E-cadherin, thereby leading to carcinogenesis. Objective To determine the antibody response of CRC patients against ETBF to ascertain whether significant difference exists or whether antibody response is related to tumor grade and tumor stage. Methods Informed consent was obtained from histologically confirmed CRC casesand their age- and sex-matched clinically healthy controls. Plasma samples from the participants were subjected to in-house enzyme-linked immunosorbent assay (ELISA) to determine their antibody levels. Results Using ETBF total protein as coating antigen, 38/39 (97%) CRC cases and 36/39 (92%) controls showed anti-ETBF IgG above cut-off, while all (100%) CRC cases and 36/39 (92%) controls had anti-ETBF IgA levels above cut-off. With culture broth as coating antigen, all (100%) CRC cases and 37/39 (95%) controls had anti-ETBF IgG levels above cut-off. For anti-ETBF IgA, all (100%) cases and controls had levels above cut-off. Statistical analysis reveals no significant difference (P > 0.05) on the number of CRC cases and controls with IgG and IgA antibody levels above cut-off value. Also, there's no significant difference (P > 0.05) in the mean anti-ETBF antibody levels of cases who were at different tumor grade (well differentiated and moderately and poorly differentiated) and tumor stage (early and advanced). Conclusions These results suggest that Filipino CRC cases and their clinically healthy matched controls exhibit antibody responses against ETBF.","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Biomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/abm-2023-0070","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background Several species of the gut microbiota have been implicated in colorectal cancer (CRC) development. The anaerobic bacterium enterotoxigenic Bacteroides fragilis (ETBF), has been identified to produce fragilysin, a toxin known to cleave E-cadherin, thereby leading to carcinogenesis. Objective To determine the antibody response of CRC patients against ETBF to ascertain whether significant difference exists or whether antibody response is related to tumor grade and tumor stage. Methods Informed consent was obtained from histologically confirmed CRC casesand their age- and sex-matched clinically healthy controls. Plasma samples from the participants were subjected to in-house enzyme-linked immunosorbent assay (ELISA) to determine their antibody levels. Results Using ETBF total protein as coating antigen, 38/39 (97%) CRC cases and 36/39 (92%) controls showed anti-ETBF IgG above cut-off, while all (100%) CRC cases and 36/39 (92%) controls had anti-ETBF IgA levels above cut-off. With culture broth as coating antigen, all (100%) CRC cases and 37/39 (95%) controls had anti-ETBF IgG levels above cut-off. For anti-ETBF IgA, all (100%) cases and controls had levels above cut-off. Statistical analysis reveals no significant difference (P > 0.05) on the number of CRC cases and controls with IgG and IgA antibody levels above cut-off value. Also, there's no significant difference (P > 0.05) in the mean anti-ETBF antibody levels of cases who were at different tumor grade (well differentiated and moderately and poorly differentiated) and tumor stage (early and advanced). Conclusions These results suggest that Filipino CRC cases and their clinically healthy matched controls exhibit antibody responses against ETBF.

查看原文本刊更多论文

菲律宾结直肠癌患者对肠毒性脆弱拟杆菌的抗体反应

背景肠道微生物群中有几种与结直肠癌（CRC）的发生有关。已发现厌氧菌肠毒性脆弱拟杆菌（ETBF）可产生脆弱素，这种毒素可裂解 E-粘连蛋白，从而导致癌变。目的测定 CRC 患者对 ETBF 的抗体反应，以确定是否存在显著差异，或抗体反应是否与肿瘤分级和肿瘤分期有关。方法获得组织学确诊的 CRC 病例及其年龄和性别匹配的临床健康对照组的知情同意。参与者的血浆样本经内部酶联免疫吸附试验（ELISA）测定其抗体水平。结果以 ETBF 总蛋白为包被抗原，38/39 例（97%）CRC 病例和 36/39 例（92%）对照组的抗 ETBF IgG 超过临界值，而所有（100%）CRC 病例和 36/39 例（92%）对照组的抗 ETBF IgA 水平均超过临界值。以培养肉汤为包被抗原时，所有（100%）CRC 病例和 37/39 例（95%）对照组的抗ETBF IgG 水平均高于临界值。所有病例（100%）和对照组的抗 ETF IgA 水平均高于临界值。统计分析表明，IgG 和 IgA 抗体水平高于临界值的 CRC 病例和对照组人数无明显差异（P > 0.05）。此外，不同肿瘤分化程度（分化良好、中度和分化不良）和肿瘤分期（早期和晚期）的病例的平均抗 ETF 抗体水平也无明显差异（P > 0.05）。结论这些结果表明，菲律宾籍的 CRC 病例及其临床健康的匹配对照均表现出抗 ETBF 的抗体反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Biomedicine 医学-医学：研究与实验

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Asian Biomedicine: Research, Reviews and News (ISSN 1905-7415 print; 1875-855X online) is published in one volume (of 6 bimonthly issues) a year since 2007. [...]Asian Biomedicine is an international, general medical and biomedical journal that aims to publish original peer-reviewed contributions dealing with various topics in the biomedical and health sciences from basic experimental to clinical aspects. The work and authorship must be strongly affiliated with a country in Asia, or with specific importance and relevance to the Asian region. The Journal will publish reviews, original experimental studies, observational studies, technical and clinical (case) reports, practice guidelines, historical perspectives of Asian biomedicine, clinicopathological conferences, and commentaries Asian biomedicine is intended for a broad and international audience, primarily those in the health professions including researchers, physician practitioners, basic medical scientists, dentists, educators, administrators, those in the assistive professions, such as nurses, and the many types of allied health professionals in research and health care delivery systems including those in training.